You Are What You Drink

Article

For 5 decades, Maine, Vermont, and New Hampshire have reported a 20% higher rate of bladder cancer than the United States overall. A recent extensive population-based, case-control study sought to evaluate suspected risk factors for these findings -- namely, the presence of arsenic in drinking water from private wells.

For 5 decades, Maine, Vermont, and New Hampshire have reported a 20% higher rate of bladder cancer than the United States overall.1 A recent extensive population-based, case-control study sought to evaluate suspected risk factors for these findings – namely, the presence of arsenic in drinking water from private wells. Patients with bladder cancer (n = 1,213) and control subjects (1,418) in these states were compared.

Study participants who consumed water from private wells (particularly shallow dug wells which are vulnerable to contamination from arsenical pesticides) were associated with heightened risk for bladder cancer.1 The International Agency for Research on Cancer (IARC) has classified inorganic arsenic in drinking water as a Group 1 carcinogen.2 In their review of 3 decades of research on arsenic exposure in drinking water, Canadian researchers also reported heightened risk for renal cancer.3 Unclear is the additive risk effect of tobacco exposure, another major etiology of urological primaries, in patients diagnosed with these cancers.

Another study sought to identify the relationship between the intake of sugar-sweetened beverages (SSB) with endometrial cancer. These epidemiologists from Minnesota and the District of Columbia evaluated the dietary intake of sugar-sweetened beverages, fruit juice, sugar-free beverages, sweets/baked goods, starch and sugars, among over 23,000 postmenopausal women participating in the Iowa Women’s Health Study.4 Higher intake of SSB and sugars was associated with an increased risk of type I endometrial cancer, the variant which is estrogen-dependent and more clinically aggressive than type II endometrial cancer. The researchers acknowledged previous investigations linking diabetes and obesity with endometrial carcinogenesis.5-7

Of note is that SSBs are the leading source of added sugars in the American diet and that SSB consumption directly parallels the increasing prevalence of obesity in the United States.8-10

An enhanced focus on prevention is a priority strategy to reduce the global burden of cancer.11As oncology nurses, we owe it to our patients to educate them about current findings within the realm of cancer prevention research. Not only does increased education empower them with knowledge, it also empowers them to engage in positive lifestyle behaviors and decisions that potentially augment their recovery and future health.

References:

  • Baris D, Waddekk R, Beane Freeman LE, et al. Elevated bladder Cancer in Northern New England: The Role of Drinking Water and Arsenic. J Natl Cancer Inst. 2016 May 2;108(9).
  • International Agency for Research on Cancer. IARC: Monographs on the Evaluation of Carcinogenic Risks to Humans: Drinking Water Disinfectants and Contaminants, including Arsenic. (2007).
  • Saint-Jacques N, Parker L, Brown P, Dummer TJ. Arsenic in drinking water and urinary tract cancers: A systematic review of 30 years of epidemiological evidence. Environ Health. 2014 Jun 2;13:44.
  • Inoue-Choi M, Robien K, Mariani A, et al. Sugar-sweetened beverage intake and the risk of type I and type II endometrial cancer among post-menopausal women. Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2384-94.
  • Lambe M, Wigertz A, Garmo H, et al. Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes Control. 2011 Aug;22(8):1163-71.
  • Lai GY, Park Y, Hartge P, et al. The association between self-reported diabetes and cancer incidence in the NIH-AARP Diet and Health Study. J Clin Endocrinol Metab. 2013 Mar;98(3):E497-502.
  • Zhang ZH, Su PY, Hao JH, Sun YH. The role of pre-existing diabetes mellitus on incidence and mortality of endometrial cancer: A meta-analysis of prospective cohort studies. Int J Gynecol Cancer. 2013 Feb;23(2):294-303.
  • Guthrie JF, Morton JF. Food sources of added sweeteners in the diets of Americans. J Am Diet Assoc. 2000 Jan;100(1):43-51, quiz 49-50.
  • Schulze MB, Manson JE, Ludwig DS, et al. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA. 2004 Aug 25;292(8):927-34.
  • Vartanian LR, Schwartz MB, Brownell KD. Effects of soft drink consumption on nutrition and health: A systematic review and meta-analysis. Am J Public Health. 2007 Apr;97(4):667-75.
  • Meyskens FL, Mukhtar H, Rock CL, et al. Cancer Prevention: Obstacles, Challenges, and the Road Ahead. J Natl Cancer Inst. (2016) 108 (2): djv309.
Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
Related Content
Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers | Image Credit: © freshidea - stock.adobe.com.

Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers

April 24th 2024
Article

The FDA has set a Prescription Drug User Fee Act date of August 23, 2024, for dostarlimab in all types of primary advanced endometrial cancer.

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical Cancer

January 22nd 2024
Podcast

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Ixabepilone Combo Improves PFS/OS in Platinum-Resistant Ovarian Cancer

March 28th 2024
Article

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

September 18th 2023
Podcast

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Nab-Sirolimus appears to produce responses in patients with perivascular epithelioid sarcoma regardless of TSC1/TSC2 mutation status.

Nab-Sirolimus Yields Sustained Responses in Gynecologic Sarcomas

March 20th 2024
Article

Nab-Sirolimus appears to produce responses in patients with perivascular epithelioid sarcoma regardless of TSC1/TSC2 mutation status.

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.

CRX100 Yields Responses, Tolerability in Platinum-Resistant Ovarian Cancer

March 19th 2024
Article

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.